Eupraxia Pharmaceuticals (NASDAQ:EPRX) Shares Cross Below Two Hundred Day Moving Average - Here's What Happened

Eupraxia Pharmaceuticals logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Eupraxia shares fell below their 200-day moving average, trading as low as $6.50 and last at $6.62, versus the average of $7.23.
  • Analysts’ consensus rating is “Moderate Buy,” with an average price target of $18.00. Recent ratings range from a sell to strong buy, and HC Wainwright raised its target to $16.
  • The company reported a quarterly loss of $0.23 per share, beating analysts’ estimate of a $0.26 loss by $0.03.
  • MarketBeat previews top five stocks to own in December.

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX - Get Free Report)'s share price crossed below its two hundred day moving average during trading on Tuesday. The stock has a two hundred day moving average of $7.23 and traded as low as $6.50. Eupraxia Pharmaceuticals shares last traded at $6.62, with a volume of 1,635,037 shares changing hands.

Analyst Upgrades and Downgrades

EPRX has been the topic of several recent research reports. HC Wainwright increased their target price on shares of Eupraxia Pharmaceuticals from $11.00 to $16.00 and gave the company a "buy" rating in a report on Wednesday, November 11th. Stifel Nicolaus set a $25.00 price target on shares of Eupraxia Pharmaceuticals in a research note on Thursday, September 24th. Cantor Fitzgerald restated an "overweight" rating on shares of Eupraxia Pharmaceuticals in a research report on Thursday, October 8th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Eupraxia Pharmaceuticals in a research note on Thursday, October 15th. Finally, Wedbush reiterated an "outperform" rating on shares of Eupraxia Pharmaceuticals in a report on Monday. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $18.00.

Get Our Latest Research Report on EPRX

Eupraxia Pharmaceuticals Price Performance

The business has a fifty day simple moving average of $7.59 and a two-hundred day simple moving average of $7.23. The company has a current ratio of 12.25, a quick ratio of 12.25 and a debt-to-equity ratio of 0.03. The stock has a market cap of $445.13 million, a PE ratio of -6.25 and a beta of 1.04.

Eupraxia Pharmaceuticals (NASDAQ:EPRX - Get Free Report) last announced its earnings results on Tuesday, November 10th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.26) by $0.03. Research analysts forecast that Eupraxia Pharmaceuticals Inc. will post -0.86 earnings per share for the current year.

Institutional Investors Weigh In On Eupraxia Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Bellevue Group AG purchased a new stake in shares of Eupraxia Pharmaceuticals in the 3rd quarter worth about $23,616,000. Affinity Asset Advisors LLC increased its stake in shares of Eupraxia Pharmaceuticals by 429.7% in the 1st quarter. Affinity Asset Advisors LLC now owns 1,589,005 shares of the company's stock worth $11,504,000 after acquiring an additional 1,289,005 shares in the last quarter. Jupiter Topco LLC bought a new position in shares of Eupraxia Pharmaceuticals in the 2nd quarter worth about $6,851,000. Seven Fleet Capital Management LP bought a new position in shares of Eupraxia Pharmaceuticals in the 1st quarter worth about $5,137,000. Finally, Redmile Group LLC bought a new position in shares of Eupraxia Pharmaceuticals in the 1st quarter worth about $5,068,000.

Eupraxia Pharmaceuticals Company Profile

(Get Free Report)

Eupraxia Pharmaceuticals is a clinical-stage biotechnology company developing treatments that use its DiffuSphere drug-delivery technology. The polymer-based platform is designed to release medicines over an extended period and deliver them locally to targeted tissues. The company's lead candidate, EP-104IAR, is an extended-release formulation of fluticasone propionate being developed as an injection into the knee for people with osteoarthritis. Eupraxia is also exploring applications of its delivery platform in other conditions, including eosinophilic esophagitis.

Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Eupraxia Pharmaceuticals Right Now?

Before you consider Eupraxia Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eupraxia Pharmaceuticals wasn't on the list.

While Eupraxia Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Best Stocks to Own in Fall 2026 Cover

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines